PARP1 and ovarian carcinoma: Among these, PARP inhibitors have shown therapeutic merit whether it is as a monotherapy or in combination with cytotoxic agents, with olaparib being the furthest progressed into clinical development and recently FDA-approved for use in women with BRCA-associated ovarian cancer.